<DOC>
	<DOCNO>NCT00158821</DOCNO>
	<brief_summary>To compare tenofovir DF plus lamivudine plus efavirenz vs. stavudine plus lamivudine plus efavirenz treatment HIV-1-infected patient never take antiretroviral drug viral load le 400 copies/mL week 48 .</brief_summary>
	<brief_title>Study Treatment Antiretroviral-naive , HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered Combination With Lamivudine Efavirenz vs. Stavudine , Lamivudine Efavirenz .</brief_title>
	<detailed_description>To compare two treatment group goal achieve HIV-1 RNA level less 50 copies/mL week 48 . To compare safety , efficacy tolerability two treatment regimens 144 week drug exposure . To evaluate long-term efficacy , safety tolerability tenofovir DF combination lamivudine efavirenz approximately 336 week drug exposure .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Completed original 96weeks openlabel treatment . Willingness use effective contraception male female study treatment 30 day follow study drug completion . The ability understand sign write informed consent form , must obtain prior initiation study procedure relate second 96week openlabel phase extension . Patients require therapy following : Nephrotoxic agent ( aminoglycoside antibiotic , IV amphotericin B , cidofovir , cisplatin , foscarnet , IV pentamidine , oral IV vancomycin , oral IV ganciclovir , agent significant nephrotoxic potential ) ; Probenecid ; Systemic chemotherapeutic agent ; Systemic corticosteroid ; Interleukin2 ( IL2 ) ; Investigational agent ( except approval Gilead Sciences ) ; Drugs interact efavirenz ( astemizole , terfenadine , dihydroergotamine , ergotamine , midazolam , triazolam , cisapride , rifampin , ergonovine , methylergonovine , voriconazole ) . Administration list medication allow throughout duration study period . Pregnant lactating patient . Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication . Current alcohol substance abuse judge investigator potentially interfere patient compliance . Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Patients biopsyconfirmed cutaneous KS eligible , anticipated require systemic therapy study . Active , serious infection ( HIV1 infection ) require parenteral antibiotic therapy . Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study unable comply dose requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV-1</keyword>
</DOC>